His primary scientific interests are in Virology, Antibody, Immunology, Neutralization and Epitope. As a part of the same scientific study, Robert T. Bailer usually deals with the Virology, concentrating on Gp41 and frequently concerns with Viral entry and Protein structure. He combines subjects such as Regimen and Immune system with his study of Antibody.
Robert T. Bailer interconnects Viral vector and HIV vaccine, Acquired immunodeficiency syndrome in the investigation of issues within Immunology. His Neutralization study integrates concerns from other disciplines, such as Molecular biology, Potency and Binding site. His Epitope research incorporates themes from Peptide sequence and Somatic hypermutation.
His primary areas of study are Virology, Antibody, Immunology, Epitope and Neutralization. His specific area of interest is Virology, where Robert T. Bailer studies Virus. In his research, Binding site, Protein structure and Mutation is intimately related to Glycan, which falls under the overarching field of Antibody.
His Immunology study typically links adjacent topics like HIV vaccine. His Epitope research is multidisciplinary, incorporating elements of Lineage, Viral entry and B cell. His research in Neutralization intersects with topics in Viral envelope, Glycoprotein, In vitro, Potency and Paratope.
His primary areas of investigation include Antibody, Virology, Epitope, Neutralization and Internal medicine. His Antibody research includes elements of Immune system and Glycan. His biological study spans a wide range of topics, including Immunogen, Immunization, Immunology and B cell.
Robert T. Bailer has included themes like HVTN 505 and Vector in his Immunology study. As a part of the same scientific family, Robert T. Bailer mostly works in the field of Epitope, focusing on Lineage and, on occasion, Affinity maturation. His Internal medicine research integrates issues from Reactogenicity and Vaccination.
Robert T. Bailer mostly deals with Antibody, Virology, Epitope, Virus and Monoclonal antibody. His work on Neutralization is typically connected to Protein engineering as part of general Antibody study, connecting several disciplines of science. His study looks at the relationship between Virology and fields such as Immunology, as well as how they intersect with chemical problems.
The Epitope study combines topics in areas such as Lineage, Somatic hypermutation, Neutralizing antibody and Affinity maturation. His Virus study combines topics from a wide range of disciplines, such as In vitro, Potency, Hiv 1 envelope and Antigen. In his study, Adverse effect and Clinical trial is strongly linked to myalgia, which falls under the umbrella field of Monoclonal antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
Barton F. Haynes;Peter B. Gilbert;M. Juliana McElrath;Susan Zolla-Pazner.
The New England Journal of Medicine (2012)
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
Jinghe Huang;Gilad Ofek;Leo Laub;Mark K. Louder.
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
Marie Pancera;Tongqing Zhou;Aliaksandr Druz;Ivelin S. Georgiev.
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.
Nicole A. Doria-Rose;Chaim A. Schramm;Jason Gorman;Penny L. Moore.
Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses
Melissa L. Precopio;Michael R. Betts;Janie Parrino;David A. Price.
Journal of Experimental Medicine (2007)
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Jinghe Huang;Byong H. Kang;Marie Pancera;Jeong Hyun Lee.
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch;Eli Boritz;Emily E. Coates;Adam DeZure.
Science Translational Medicine (2015)
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.
Marcella Sarzotti-Kelsoe;Robert T. Bailer;Ellen Turk;Chen-li Lin.
Journal of Immunological Methods (2014)
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
Katharine J Bar;Michael C Sneller;Linda J Harrison;J Shawn Justement.
The New England Journal of Medicine (2016)
Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector
Andrew T. Catanzaro;Richard A. Koup;Mario Roederer;Robert T. Bailer.
The Journal of Infectious Diseases (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: